Application of PCR-LDR-nucleic acid detection strip in detection of YMDD mutation in hepatitis B patients treated with lamivudine

Journal of Medical Virology

Volumn 82, Issue 7, 2010, Pages 1143-1149

  Xu, Gaolian ^a   You, Qimin ^a   Pickerill, Sam ^b   Zhong, Huayan ^a   Wang, Hongying ^a   Shi, Jian ^a   Luo, Ying ^a   You, Paul ^a   Kong, Huimin ^c   Lu, Fengmin ^d   Hu, Lin ^a  

^a Ustar Biotechnologies (Hangzhou) Co Ltd   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c BioHelix Corporation   (United States)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

HBV; Ligase detection reaction; Nucleic acid detection strip

Indexed keywords

ASPARTIC ACID; LAMIVUDINE; METHIONINE; TYROSINE; ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; TEST STRIP; VIRUS DNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DENATURATION; DNA HYBRIDIZATION; GENE MUTATION; HEPATITIS B; HUMAN; INTERMETHOD COMPARISON; LIGASE CHAIN REACTION; NUCLEIC ACID ANALYSIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ANTIVIRAL RESISTANCE; DRUG EFFECTS; EVALUATION STUDY; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; MUTATION; PROCEDURES; SENSITIVITY AND SPECIFICITY; TEST STRIP; VIROLOGY;

HEPATITIS B VIRUS;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIGASE CHAIN REACTION; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REAGENT STRIPS; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY;

EID: 77954394158     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21811     Document Type: Article

References (35)

1. Aberle SW, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stockl E. 2001. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 39:1972-1974.
2. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677. (Pubitemid 28264693)
3. Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, Ross LL, Lutz MW, Condreay LD. 1999. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 37:3338-3347. (Pubitemid 29455230)
4. Bozdayi AM, Uzunalimoǧlu Ö, Türkyilmaz AR, Aslan N, Sezgin O, Sahin T, Bozdayi G, Cinar K, Pai SB, Pai R, Bozkaya H, Karayalçin S, Yurdaydin C, Schinazi RF. 2003. YSDD: A novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 10:256-265.
5. Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27: 1711-1716.
6. Chen LY, Huang J, Zhang XP, Qiao P, Zhang W, Yang NM, Liu HJ, Geng YY, Qiu JM, Wang SQ. 2005. Clinical evaluation of oligonucleotide microarrays for the detection of HBV mutants associated with lamivudine resistance. Pharmacogenomics 6:721-730.
7. Chow WH, McCloskey C, Tong Y, Hu L, You Q, Kelly CP, Kong H, Tang YW, Tang W. 2008. Application of isothermal helicase-dependent amplification with a disposable detection device in a simple sensitive stool test for toxigenic Clostridium difficile. J Mol Diagn 10:452-458.
8. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. 2004. Global epidemiology of hepatitis Bvirus. J Clin Gastroenterol 38:S158-S168.
9. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS. 2009. Sensitivity and accuracy of an updated line probe assay (HBV DRv. 3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol 50:42-48.
10. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
11. Dienstag JL, Schiff ER, Mitchell M, Casey DE, Jr., Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M, Brown N. 1999. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy. Hepatology 30:1082-1087.
12. Goldmeyer J, Li H, McCormac M, Cook S, Stratton C, Lemieux B, Kong H, Tang W, Tang YW. 2008. Identification of Staphylococcus aureus and determination of methicillin resistance directly from positive blood cultures by isothermal amplification and a disposable detection device. J Clin Microbiol 46:1534-1536.
13. Gust ID. 1996. Epidemiology ofhepatitis B infection in the Western Pacific and South East Asia. Gut 38:S18-S23. (Pubitemid 26167500)
14. Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US. 2004. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci 19:541-546.
15. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, Kim HT, Rim KS, Kang MS, Yoo W, Kim SO. 2004. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 40:837-844.
16. Jang H, Cho M, Heo J, Kim H, Jun H, Shin W, Cho B, Park H, Kim C. 2004. Oligonucleotide chip for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 42:4181-4188. (Pubitemid 39296143)
17. Jardi R, Buti M, Rodriguez-Frias F, Cotrina M, Costa X, Pascual C, Esteban R, Guardia J. 1999. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Methods 83:181-187. (Pubitemid 29528556)
18. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T, Minami M. 2002. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 37:259-265.
19. Kobayashi S, Ide T, SataM. 2001. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 34:584-586.
20. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
21. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828-834.
22. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. 2001. Extended lamivudine treatment in patients with chronic hepatitis Benhances hepatitis Be antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527-1532.
23. Lindstrom A, Odeberg J, Albert J. 2004. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 42:4788-4795.
24. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
25. Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E. 2002. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNOLiPA HBV DR assay. J Clin Microbiol 40:3729-3734.
26. Niesters HG, Honkoop P, Haagsma EB, De Man RA, Schalm SW, Osterhaus AD. 1998. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 177:1382-1385.
27. Ntziora F, Paraskevis D, Haida C, Magiorkinis E, Manesis E, Papatheodoridis G, Manolakopoulos S, Beloukas A, Chryssoy S, Magiorkinis G, Sypsa V, Hatzakis A. 2009. Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology. J Clin Microbiol 47:2544-2550.
28. Sanchez JA, Pierce KE, Rice JE, Wangh LJ. 2004. Linear-after-the- exponential (LATE)-PCR: An advanced method of asymmetric PCR and its uses in quantitative real-time analysis. Proc Natl Acad Sci 101:1933-1938.
29. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R. 2000. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 38:702-707.
30. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
31. WHO. 2009. Hepatitis B: World Health Organization Fact Sheet. Geneva, Switzerland: World Health Organization.
32. Woo HY, Park H, Kim BI, Jeon WK, Kim YJ. 2008. Evaluation of dual priming oligonucleotide-based multiplex PCR for detection of HBV YMDD mutants. Arch Virol 153:2019-2025.
33. Xiao Z, Xiao J, Jiang Y, Zhang S, Yu M, Zhao J, Wei D, Cao H. 2006. A novel method based on ligase detection reaction for low abundant YIDD mutants detection in hepatitis B virus. Hepatol Res 34:150-155.
34. Zhang M, Gong Y, Osiowy C, Minuk GY. 2002. Rapid detection of hepatitis B virus mutations using real-time PCR andmelting curve analysis. Hepatology 36:723-728.
35. Zoulim F. 2001. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 21:243-253.